Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)
Price and Volume
Detailed Quote| Volume | 607,366 |
| Open | 28.15 |
| Bid (Size) | 27.00 (300) |
| Ask (Size) | 29.40 (100) |
| Prev. Close | 28.15 |
| Today's Range | 27.07 - 29.19 |
| 52wk Range | 10.60 - 30.48 |
| Shares Outstanding | 105,341,296 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
Let's take a look at the stocks that are in motion in today's session. ↗
December 24, 2025
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
November 28, 2025
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
November 27, 2025
Frequently Asked Questions
Is Edgewise Therapeutics, Inc. - Common Stock publicly traded?
Yes, Edgewise Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Edgewise Therapeutics, Inc. - Common Stock trade on?
Edgewise Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Edgewise Therapeutics, Inc. - Common Stock?
The ticker symbol for Edgewise Therapeutics, Inc. - Common Stock is EWTX on the Nasdaq Stock Market
What is the current price of Edgewise Therapeutics, Inc. - Common Stock?
The current price of Edgewise Therapeutics, Inc. - Common Stock is 28.89
When was Edgewise Therapeutics, Inc. - Common Stock last traded?
The last trade of Edgewise Therapeutics, Inc. - Common Stock was at 02/02/26 04:00 PM ET
What is the market capitalization of Edgewise Therapeutics, Inc. - Common Stock?
The market capitalization of Edgewise Therapeutics, Inc. - Common Stock is 3.04B
How many shares of Edgewise Therapeutics, Inc. - Common Stock are outstanding?
Edgewise Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
Facebook
Twitter
YouTube